Carbenoxolone-d4
Based on 1 Customer Validation
Carbenoxolone-d4 is the d4 labeled Carbenoxolone (HY-B1588). Carbenoxolone is a blood-brain barrier-permeable Pannexin1 inhibitor, gap junction (Gap junction) blocker, and β-amyloid 42 inhibitor. Carbenoxolone modulates voltage-gated currents of wild-type and mutant Panx1, and inhibits stimulus-activated Panx1 channel function. Carbenoxolone interacts with stable residues of β-amyloid 42 peptides, fibrils and oligomers, thereby inhibiting their aggregation. Carbenoxolone alleviates liver fibrosis. Carbenoxolone exerts neuroprotective and nootropic effects. Carbenoxolone can be used in studies related to Alzheimer's disease and liver fibrosis.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.28%
- Formule: C34H46D4O7
- Masse moléculaire:574.78
-
Stockage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
Activité biologique
1. This compound can be used as a tracer
2. This compound can be used as an internal standard for quantitative analysis by NMR, GC-MS, or LC-MS.
Chemical Information
-
Unlabeled Cas 5697-56-3
-
Appearance Solid
-
Masse moléculaire 574.78
-
Formule C34H46D4O7
-
Color White to off-white
-
SMILES
C[C@]12[C@@](C(C=C3[C@]2(CC[C@@]4([C@@]3([H])C[C@](C)(CC4)C(O)=O)C)C)=O)([H])[C@@]5([C@@](C(C)([C@H](CC5)OC(C([2H])([2H])C([2H])([2H])C(O)=O)=O)C)([H])CC1)C
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Pureté et documentation
-
Fiche technique (270 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Michalski K, et al. Carbenoxolone inhibits Pannexin1 channels through interactions in the first extracellular loop. J Gen Physiol. 2016;147(2):165-174. [Content Brief]
[2]. Sharma S, et al. Inhibition of Alzheimer's amyloid-beta aggregation in-vitro by carbenoxolone: Insight into mechanism of action. Neurochem Int. 2017;108:481-493. [Content Brief]
[3]. Crespo Yanguas S, et al. TAT-Gap19 and Carbenoxolone Alleviate Liver Fibrosis in Mice. Int J Mol Sci. 2018;19(3):817. Published 2018 Mar 12. [Content Brief]
[4]. Hirata K, et al. Formulation of carbenoxolone for delivery to the skin. Int J Pharm. 2013;448(2):360-365. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)